Company / Operating Cash Flow
Oruka Therapeutics, Inc. Operating Cash Flow History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$57.8M
FY2024
5-year range
-$57.8M / -$4.8M
FY2020-FY2024
Trend
-1053.5%
vs FY2023
Sector context
#99 of 216
Health Care
What the data says
Operating Cash Flow changed -1054% YoY in FY2024, a notable deviation from the 9-year average annual change of -129%.
Based on SEC 10-K filings.
-$58M in FY2024.
Declined from -$19M to -$58M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#99 of 216 in Health CareTop 46% of 216This company -$57.8M Sector average $659.0M
▼
-108.8% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow decreased 1053.5% year-over-year.
- Ranks #99 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$57.8M | -1053.5% |
| FY2023 | -$5.0M | +73.3% |
| FY2022 | -$18.8M | -142.9% |
| FY2021 | -$7.7M | -60.9% |
| FY2020 | -$4.8M | +41.8% |
| FY2019 | -$8.2M | +52.8% |
| FY2018 | -$17.5M | -16.6% |
| FY2017 | -$15.0M | -42.3% |
| FY2016 | -$10.5M | -12.0% |
| FY2015 | -$9.4M | -77.9% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026